StockData
Interpace Biosciences, Inc. logo

Interpace Biosciences, Inc. (IDXG) stock

IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)

Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –

Interpace Biosciences profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Interpace Biosciences's profit margin for the twelve months ending Jun 30, 2026 was 67.6%. For fiscal 2025 it was 63.5%, against 14.3% the year before. The highest annual figure on record is 79.0% in fiscal 2017.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202563.5%+49.2
FY2024Dec 31, 202414.3%+9.4
FY2023Dec 31, 20234.9%+73.8
FY2022Dec 31, 2022-69.0%+113.3
FY2021Dec 31, 2021-182.3%−100.7
FY2020Dec 31, 2020-81.6%+28.8
FY2019Dec 31, 2019-110.4%−52.4
FY2018Dec 31, 2018-58.0%−137.0
FY2017Dec 31, 201779.0%+247.1
FY2016Dec 31, 2016-168.2%−23.7
FY2015Dec 31, 2015-144.4%+993.2
FY2014Dec 31, 2014-1137.6%−1134.5
FY2013Dec 31, 2013-3.1%+17.0
FY2012Dec 31, 2012-20.1%−12.5
FY2011Dec 31, 2011-7.6%−2.5
FY2010Dec 31, 2010-5.1%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 20261.7%+8.7
Q1 FY2026Mar 31, 20268.0%−6.3
Q4 FY2025Dec 31, 2025245.6%+230.5
Q3 FY2025Sep 30, 202510.4%−3.2
Q2 FY2025Jun 30, 2025-6.9%−27.2
Q1 FY2025Mar 31, 202514.3%+7.3
Q4 FY2024Dec 31, 202415.2%+4.6
Q3 FY2024Sep 30, 202413.6%+15.7
Q2 FY2024Jun 30, 202420.2%+15.2
Q1 FY2024Mar 31, 20247.0%+1.6
Q4 FY2023Dec 31, 202310.5%+16.5
Q3 FY2023Sep 30, 2023-2.0%+1119.4
Q2 FY2023Jun 30, 20235.1%+206.4
Q1 FY2023Mar 31, 20235.3%+96.9
Q4 FY2022Dec 31, 2022-6.0%+15.6
Q3 FY2022Sep 30, 2022-1121.4%−1077.2
Q2 FY2022Jun 30, 2022-201.4%−170.5
Q1 FY2022Mar 31, 2022-91.6%−48.8
Q4 FY2021Dec 31, 2021-21.5%+62.9
Q3 FY2021Sep 30, 2021-44.2%+31.4
Q2 FY2021Jun 30, 2021-30.9%+71.6
Q1 FY2021Mar 31, 2021-42.8%+28.9
Q4 FY2020Dec 31, 2020-84.4%+168.6
Q3 FY2020Sep 30, 2020-75.6%+20.8
Q2 FY2020Jun 30, 2020-102.5%−17.9
Q1 FY2020Mar 31, 2020-71.7%−16.3
Q4 FY2019Dec 31, 2019-253.0%−179.3
Q3 FY2019Sep 30, 2019-96.4%−42.1
Q2 FY2019Jun 30, 2019-84.6%−48.2
Q1 FY2019Mar 31, 2019-55.3%+12.8
Q4 FY2018Dec 31, 2018-73.7%−525.9
Q3 FY2018Sep 30, 2018-54.3%+26.6
Q2 FY2018Jun 30, 2018-36.4%+129.4
Q1 FY2018Mar 31, 2018-68.1%−135.3
Q4 FY2017Dec 31, 2017452.2%+688.9
Q3 FY2017Sep 30, 2017-80.9%+160.4
Q2 FY2017Jun 30, 2017-165.8%–
Q1 FY2017Mar 31, 201767.1%–
Q4 FY2016Dec 31, 2016-236.7%–
Q3 FY2016Sep 30, 2016-241.3%–

More Interpace Biosciences figures

See a number that looks wrong?